Why Patient Advocacy Matters More Than Ever in Rare Disease Gene Therapy

At the Gene Therapy for Ophthalmic Disorders Summit, one theme rose above the science, the data, and the regulatory discussions: patient advocacy is no longer optional — it is essential to the development and approval of gene therapies for rare diseases. For families facing rapidly progressive vision loss from Bardet-Biedl Syndrome (BBS) or retinitis pigmentosa (RP), that message carries enormous weight. It affirms what our community already knows: progress does not happen on its own. It happens when families, nonprofits, researchers, regulators, and biotech partners push together in the same direction. This blog explores why advocacy organizations like A Race Against Blindness play a critical role in shaping the future of treatment — and why our work is not just important, but urgently needed. 1. Advocates Help Set the Direction for Research One of the clearest messages from summit speakers was that patient communities influence which therapies get pursued — and how quickly. Why? Because rare diseases lack: Large patient populations Large financial incentives for pharmaceutical comp